mCureX Therapeutics

mCureX Therapeutics, a subsidiary of leading RNAi therapeutics company OliX Pharmaceuticals, is focused on the research and development of mRNA (messenger RNA) vaccines and therapies. We possess in-house capabilities spanning proprietary technologies, preclinical and clinical development, to commercialization, as well as production expertise in designing mRNA molecular structures. Utilizing modified nucleotide technology that ensures FTO (Freedom to Operate), we have completed the selection of our lead candidate for the COVID-19 vaccine and commenced production. Based on our proprietary mRNA platform, we aim to be a pioneer in the mRNA therapeutics and vaccines market. We plan to expand our pipeline to encompass various indications, including infectious diseases such as influenza, cancer, respiratory conditions, and liver diseases.